• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Hepatitis - Articles and news items

grazoprevir/elbasvir

AbbVie receives FDA approval for new Hepatitis C drug

Industry news / 27 July 2016 / Niamh Louise Marriott, Digital Content Producer

US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C…

epclusa

FDA approves Epclusa for treatment of chronic HCV

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection…

Epclusa

Positive CHMP opinion for Gilead’s Epclusa in HCV

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus…

abt-493

AbbVie presents data for ABT-493 and ABT-530 regimen in HCV

Industry news / 18 April 2016 / Victoria White, Digital Content Producer

With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12…

hbv

Gilead announces results from two Phase III studies of TAF in HBV

Industry news / 15 April 2016 / Victoria White, Digital Content Producer

Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection…

Viekirax

AbbVie presents real-world data for Viekirax + Exviera in HCV

Industry news / 15 April 2016 / Victoria White, Digital Content Producer

AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12…

Exviera

Positive results for AbbVie’s Viekirax + Exviera regimen

Industry news / 14 April 2016 / Victoria White, Digital Content Producer

AbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients…

elbasvir

MSD announces positive results from elbasvir/grazoprevir HCV study

Industry news / 14 April 2016 / Victoria White, Digital Content Producer

Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV…

HIV-and-HCV

Combined HIV and hepatitis C virus vaccination a step closer

Industry news / 13 April 2016 / Victoria White, Digital Content Producer

A study has shown that the ‘prime boost’ approach is compatible with co-administration of vectors encoding for HIV and HCV antigens…

Viekirax

CHMP adopts positive opinion of AbbVie’s Viekirax + Exviera in HCV

Industry news / 26 February 2016 / Victoria White

The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study…

hepatitis B

Gilead’s MAA for TAF in hepatitis B now under assessment by the EMA

Industry news / 26 February 2016 / Victoria White

TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread at one-tenth of the dose…

hepatitis b

China to remain the largest hepatitis B market, says GlobalData

Industry news / 24 February 2016 / Victoria White

GlobalData says China will continue to dominate the hepatitis B treatment space, as its market share rises from 38.8% in 2014 to 47.2% by 2024…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +